SYRE Operating Cash Flow (Statement)
Spyre Therapeutics Inc · Operating Cash Flow (Statement)
SYRE Operating Cash Flow (Statement)
Latest reported-$208.94Mperiod ending
SYRE TTM Cash from Operations (-$7.34M → -$208.94M)
TTM operating cash flow (statement)
High-resolution chart · PNG
SYRE operating cash flow (statement) history
Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.
| Period ending | Operating Cash Flow (Statement) (USD) |
|---|---|
| -208,944,000 | |
| -185,630,000 | |
| -169,252,000 | |
| -161,873,000 | |
| -154,177,000 | |
| -169,862,000 | |
| -157,410,000 | |
| -151,247,000 | |
| -156,423,000 | |
| -110,818,000 | |
| -99,910,000 | |
| -87,014,000 | |
| -67,485,000 | |
| -71,515,000 | |
| -80,144,000 | |
| -81,272,000 | |
| -83,204,000 | |
| -60,449,000 | |
| -53,716,000 | |
| -51,580,000 | |
| -52,116,000 | |
| -73,611,000 | |
| -75,775,000 | |
| -74,937,000 | |
| -74,609,000 | |
| -71,579,000 | |
| -65,692,000 | |
| -56,598,000 | |
| -47,892,000 | |
| -40,553,000 | |
| -32,193,000 | |
| -30,866,000 | |
| -29,732,000 | |
| -26,630,000 | |
| -24,615,000 | |
| -23,097,000 | |
| -21,594,000 | |
| -20,284,000 | |
| -18,840,000 | |
| -15,318,000 | |
| -13,264,000 | |
| -12,487,000 | |
| -10,982,000 | |
| -13,124,000 | |
| -11,115,000 | |
| -8,477,000 | |
| -7,335,000 |